Details of the Drug

General Information of Drug (ID: DMLK2QH)

Drug Name
Nateglinide
Synonyms
Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1], [2]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 317.4
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
73% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.8 mL/min/kg [5]
Elimination
13% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.2 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.029% [5]
Vd
The volume of distribution (Vd) of drug is 10 L [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.322 mg/mL [3]
Chemical Identifiers
Formula
C19H27NO3
IUPAC Name
(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Canonical SMILES
CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
InChI
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
InChIKey
OELFLUMRDSZNSF-OFLPRAFFSA-N
Cross-matching ID
PubChem CID
5311309
ChEBI ID
CHEBI:31897
CAS Number
105816-04-4
DrugBank ID
DB00731
TTD ID
D06PSS
VARIDT ID
DR00407
INTEDE ID
DR1132
ACDINA ID
D00458

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Monocarboxylate transporter 6 (SLC16A5) DT3I124 MOT6_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [15]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [15]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [16]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nateglinide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Glibenclamide DM8JXPZ Moderate Decreased metabolism of Nateglinide caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [76]
Tolazamide DMIHRNA Moderate Decreased metabolism of Nateglinide caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [76]
Glipizide DMZA5PQ Moderate Decreased metabolism of Nateglinide caused by Glipizide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [76]
Coadministration of a Drug Treating the Disease Different from Nateglinide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metronidazole DMTIVEN Moderate Decreased metabolism of Nateglinide caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [76]
Oxymetholone DMFXUT8 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Oxymetholone. Aplastic anaemia [3A70] [77]
Alpelisib DMEXMYK Moderate Increased metabolism of Nateglinide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [78]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [77]
Fenofibric acid DMGO2MC Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [77]
Phenylbutazone DMAYL0T Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Phenylbutazone. Chronic pain [MG30] [77]
Ketoprofen DMRKXPT Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Ketoprofen. Chronic pain [MG30] [77]
Ardeparin DMYRX8B Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Ardeparin. Coronary thrombosis [BA43] [77]
Mifepristone DMGZQEF Moderate Decreased metabolism of Nateglinide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [79]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nateglinide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [80]
Sertraline DM0FB1J Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Sertraline. Depression [6A70-6A7Z] [77]
Vilazodone DM4LECQ Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Vilazodone. Depression [6A70-6A7Z] [77]
Selegiline DM6034S Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Selegiline. Depression [6A70-6A7Z] [77]
Vortioxetine DM6F1PU Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Vortioxetine. Depression [6A70-6A7Z] [77]
Isocarboxazid DMAF1NB Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Isocarboxazid. Depression [6A70-6A7Z] [77]
Escitalopram DMFK9HG Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Escitalopram. Depression [6A70-6A7Z] [77]
Tranylcypromine DMGB5RE Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Tranylcypromine. Depression [6A70-6A7Z] [77]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of hypoglycemia by the combination of Nateglinide and PMID28870136-Compound-49. Discovery agent [N.A.] [77]
Mefenamic acid DMK7HFI Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Mefenamic acid. Female pelvic pain [GA34] [77]
Miconazole DMPMYE8 Moderate Decreased metabolism of Nateglinide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [81]
Sunitinib DMCBJSR Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [77]
Sulfinpyrazone DMEV954 Minor Decreased metabolism of Nateglinide caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme. Gout [FA25] [82]
Rifapentine DMCHV4I Moderate Increased metabolism of Nateglinide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [83]
Etravirine DMGV8QU Moderate Decreased metabolism of Nateglinide caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Nateglinide caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [85]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Nateglinide caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [76]
Fenofibrate DMFKXDY Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Fenofibrate. Hyper-lipoproteinaemia [5C80] [77]
Captopril DM458UM Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Captopril. Hypertension [BA00-BA04] [77]
Perindopril DMOPZDT Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Perindopril. Hypertension [BA00-BA04] [77]
Quinapril DMR8H31 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Quinapril. Hypertension [BA00-BA04] [77]
Irbesartan DMTP1DC Moderate Decreased metabolism of Nateglinide caused by Irbesartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [76]
Probenecid DMMFWOJ Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [77]
Balsalazide DMO091F Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Balsalazide. Indeterminate colitis [DD72] [77]
Ramelteon DM7IW9J Moderate Decreased metabolism of Nateglinide caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [76]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nateglinide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [85]
Hydroxychloroquine DMSIVND Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Hydroxychloroquine. Malaria [1F40-1F45] [77]
Sulphadoxine DMZI2UF Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Sulphadoxine. Malaria [1F40-1F45] [77]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nateglinide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [85]
Mecasermin DM1O3BY Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Mecasermin. Multiple structural anomalies syndrome [LD2F] [77]
Nilotinib DM7HXWT Moderate Decreased metabolism of Nateglinide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [86]
Naproxen DMZ5RGV Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Naproxen. Osteoarthritis [FA00-FA05] [77]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nateglinide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [87]
Aspirin DM672AH Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Aspirin. Pain [MG30-MG3Z] [88]
Etodolac DM6WJO9 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Etodolac. Pain [MG30-MG3Z] [77]
Ibuprofen DM8VCBE Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Ibuprofen. Pain [MG30-MG3Z] [77]
Safinamide DM0YWJC Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Safinamide. Parkinsonism [8A00] [77]
Rasagiline DM3WKQ4 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Rasagiline. Parkinsonism [8A00] [77]
Abametapir DM2RX0I Moderate Decreased metabolism of Nateglinide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [89]
Lefamulin DME6G97 Moderate Decreased metabolism of Nateglinide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [90]
Bromfenac DMKB79O Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Bromfenac. Postoperative inflammation [1A00-CA43] [77]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Nateglinide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [91]
Enzalutamide DMGL19D Moderate Increased metabolism of Nateglinide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [92]
Salsalate DM13P4C Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Salsalate. Rheumatoid arthritis [FA20] [77]
Meloxicam DM2AR7L Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Meloxicam. Rheumatoid arthritis [FA20] [77]
Oxaprozin DM9UB0P Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Oxaprozin. Rheumatoid arthritis [FA20] [77]
Sulfasalazine DMICA9H Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Sulfasalazine. Rheumatoid arthritis [FA20] [77]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Nateglinide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [76]
Salicyclic acid DM2F8XZ Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Salicyclic acid. Seborrhoeic dermatitis [EA81] [88]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nateglinide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
Ifosfamide DMCT3I8 Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [77]
Methyltestosterone DMWLFGO Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [77]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Nateglinide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [93]
Tolbutamide DM02AWV Moderate Decreased metabolism of Nateglinide caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [76]
Pramlintide DM0EZ9Q Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Pramlintide. Type-1/2 diabete [5A10-5A11] [77]
Olsalazine DMZW9HA Moderate Increased risk of hypoglycemia by the combination of Nateglinide and Olsalazine. Ulcerative colitis [DD71] [77]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Nateglinide caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [76]
⏷ Show the Full List of 66 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nateglinide 120 mg tablet 120 mg Oral Tablet Oral
Nateglinide 60 mg tablet 60 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6833).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
11 Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
12 FDA Drug Development and Drug Interactions
13 Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
14 Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
15 Drug Interactions Flockhart Table
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
26 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
27 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
28 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
29 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
30 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
31 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
32 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
33 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
34 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
35 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
36 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
37 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
38 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
39 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
40 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
41 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
42 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
43 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
44 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
45 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
46 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
47 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
48 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
49 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
50 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
51 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
52 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
53 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
54 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
55 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
56 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
57 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
58 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
59 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
60 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
61 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
62 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
63 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
64 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
65 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
66 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
67 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
68 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
69 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
70 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
71 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
72 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
73 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
74 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
75 Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
76 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
77 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
78 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
80 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
81 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
82 Sabia H, Sunkara G, Ligueros-Saylan M, et al. "Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects." Eur J Clin Pharmacol (2004):. [PMID: 15197517]
83 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
84 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
85 Cerner Multum, Inc. "Australian Product Information.".
86 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
87 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
88 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
89 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
90 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
91 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
92 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
93 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.